P132 (Trial in Progress) A phase 2, open-label, randomized multicenter trial to evaluate neoadjuvant lasofoxifene in molecularly-selected HR+/HER2− Clinical Stage 2/3 breast cancer. (April 2023) - Chien, J.; Esserman, L.; Elias, A.; Wei, M.; Plourde, P.; Portman, D.